Error loading player: No playable sources found

Parallel Session 6A - Prior Knowledge to Support Clinical and Marketing Applications

Date
January 29, 2025
This product is not available for individual purchase, but it is available as part of the following products:

Prior knowledge is fundamental for the progression of science and critical for efficient product development and informed regulatory assessments of product safety and quality. In this session, a variety of case studies will be presented touching on aspects of modeling, extrapolation, analysis of structured and unstructured datasets and the application to product development and the assessment of regulatory submissions.  The panel will discuss successful applications of prior knowledge and explore the challenges and areas for improvement.      


Session Speakers:


How to Incorporate Prior Knowledge: What Are Bayesian Statistics and Why Non-Statisticians Should Be Interested
Christopher Thompson, AstraZeneca


Predictive Stability for Biologics Using Kinetic Modeling

Michael Dillon,  Merck & Co., Inc.


Leveraging Prior Knowledge for Efficient mRNA Vaccine Drug Product Development
Bob Walters, Pfizer, Inc.



Additional Panelists:


Jayda Siggers, Health Canada 


Jason WarfelBristol-Myers Squibb Company


Related Products

Thumbnail for Turning Mandates into Momentum: How CASSS Can Help Sonia Vallabh?
Turning Mandates into Momentum: How CASSS Can Help Sonia Vallabh?
As a follow-up to Tuesday's very impactful Keynote presentation, join us in-person or online as we come together as a community and brainstorm ways to further Sonia's mission to prevent prion disease…
Thumbnail for Parallel Session 2B- LER 2025: Strategies Today for Overcoming Low Endotoxin Recovery
Parallel Session 2B- LER 2025: Strategies Today for Overcoming Low Endotoxin Recovery
Monitoring and control of endotoxin are critical aspects of an overall microbial control strategy necessary to ensure drug product quality and patient safety…
Thumbnail for Parallel Session 5B - Immunogenicity Risk and Control
Parallel Session 5B - Immunogenicity Risk and Control
Peptides, proteins and oligonucleotide are becoming essential medical treatments for many progressive, debilitating, or life-threatening diseases. However, the development of these potential therapies can be derailed by product immunogenicity as it can impact on safety and efficacy…